agalsidase beta
ApprovedTerminated 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Fabry Disease
Conditions
Fabry Disease, Alpha Galactosidase A Deficiency
Trial Timeline
May 28, 2006 → Feb 9, 2024
NCT ID
NCT00230607About agalsidase beta
agalsidase beta is a approved stage product being developed by Sanofi for Fabry Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT00230607. Target conditions include Fabry Disease, Alpha Galactosidase A Deficiency.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05054387 | Approved | Completed |
| NCT01650779 | Approved | Completed |
| NCT00230607 | Approved | Terminated |
| NCT00140621 | Approved | Completed |
| NCT00081497 | Approved | Completed |
Competing Products
20 competing products in Fabry Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lucerastat | Idorsia | Phase 3 | 72 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 51 |
| Venglustat (GZ402671) + Placebo | Sanofi | Phase 3 | 76 |
| Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 51 |
| Tropicamide | Sanofi | Pre-clinical | 22 |
| Fabrazyme (agalsidase beta) | Sanofi | Approved | 84 |
| agalsidase beta | Sanofi | Approved | 84 |
| AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + Fexofenadine | Sanofi | Approved | 84 |
| Gabapentin + placebo | Sanofi | Phase 2 | 51 |
| Agalsidase beta | Sanofi | Approved | 84 |
| GZ/SAR402671 | Sanofi | Phase 2 | 51 |
| agalsidase beta (GZ419828) + agalsidase alfa | Sanofi | Approved | 84 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 3 | 76 |
| Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + Migalastat | Sanofi | Phase 3 | 76 |
| Iohexol | Sanofi | Phase 1 | 32 |
| GZ/SAR402671 | Sanofi | Phase 2 | 51 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 51 |
| Agalsidase beta | Sanofi | Approved | 84 |
| Fabrazyme (agalsidase beta) + Placebo | Sanofi | Approved | 84 |
| Agalsidase beta + Agalsidase beta | Sanofi | Phase 3 | 76 |